Antidepressant medicine use and risk of developing diabetes during the diabetes prevention program and diabetes prevention program outcomes study

Richard R. Rubin, Yong Ma, Mark Peyrot, David Marrero, David W. Price, Elizabeth Barrett-Connor, William C. Knowler

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

OBJECTIVE - To assess the association between antidepressant medicine use and risk of developing diabetes during the Diabetes Prevention Program (DPP) and Diabetes Prevention Program Outcomes Study (DPPOS). RESEARCH DESIGN AND METHODS - DPP/DPPOS participants were assessed for diabetes every 6 months and for antidepressant use every 3 months in DPP and every 6 months in DPPOS for a median 10.0-year follow-up. RESULTS - Controlled for factors associated with diabetes risk, continuous antidepressant use compared with no use was associated with diabetes risk in the placebo (adjusted hazard ratio 2.34 [95% CI 1.32-4.15]) and lifestyle (2.48 [1.45-4.22]) arms, but not in the metformin arm (0.55 [0.25-1.19]). CONCLUSIONS - Continuous antidepressant use was significantly associated with diabetes risk in the placebo and lifestyle arms. Measured confounders and mediators did not account for this association, which could represent a drug effect or reflect differences not assessed in this study between antidepressant users and nonusers.

Original languageEnglish
Pages (from-to)2549-2551
Number of pages3
JournalDiabetes Care
Volume33
Issue number12
DOIs
StatePublished - Dec 2010

Fingerprint

Antidepressive Agents
Medicine
Outcome Assessment (Health Care)
Life Style
Placebos
Metformin
Research Design
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialized Nursing

Cite this

Antidepressant medicine use and risk of developing diabetes during the diabetes prevention program and diabetes prevention program outcomes study. / Rubin, Richard R.; Ma, Yong; Peyrot, Mark; Marrero, David; Price, David W.; Barrett-Connor, Elizabeth; Knowler, William C.

In: Diabetes Care, Vol. 33, No. 12, 12.2010, p. 2549-2551.

Research output: Contribution to journalArticle

Rubin, Richard R. ; Ma, Yong ; Peyrot, Mark ; Marrero, David ; Price, David W. ; Barrett-Connor, Elizabeth ; Knowler, William C. / Antidepressant medicine use and risk of developing diabetes during the diabetes prevention program and diabetes prevention program outcomes study. In: Diabetes Care. 2010 ; Vol. 33, No. 12. pp. 2549-2551.
@article{abb2d0e4b62c4247a9bf8feb49250ceb,
title = "Antidepressant medicine use and risk of developing diabetes during the diabetes prevention program and diabetes prevention program outcomes study",
abstract = "OBJECTIVE - To assess the association between antidepressant medicine use and risk of developing diabetes during the Diabetes Prevention Program (DPP) and Diabetes Prevention Program Outcomes Study (DPPOS). RESEARCH DESIGN AND METHODS - DPP/DPPOS participants were assessed for diabetes every 6 months and for antidepressant use every 3 months in DPP and every 6 months in DPPOS for a median 10.0-year follow-up. RESULTS - Controlled for factors associated with diabetes risk, continuous antidepressant use compared with no use was associated with diabetes risk in the placebo (adjusted hazard ratio 2.34 [95{\%} CI 1.32-4.15]) and lifestyle (2.48 [1.45-4.22]) arms, but not in the metformin arm (0.55 [0.25-1.19]). CONCLUSIONS - Continuous antidepressant use was significantly associated with diabetes risk in the placebo and lifestyle arms. Measured confounders and mediators did not account for this association, which could represent a drug effect or reflect differences not assessed in this study between antidepressant users and nonusers.",
author = "Rubin, {Richard R.} and Yong Ma and Mark Peyrot and David Marrero and Price, {David W.} and Elizabeth Barrett-Connor and Knowler, {William C.}",
year = "2010",
month = "12",
doi = "10.2337/dc10-1033",
language = "English",
volume = "33",
pages = "2549--2551",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "12",

}

TY - JOUR

T1 - Antidepressant medicine use and risk of developing diabetes during the diabetes prevention program and diabetes prevention program outcomes study

AU - Rubin, Richard R.

AU - Ma, Yong

AU - Peyrot, Mark

AU - Marrero, David

AU - Price, David W.

AU - Barrett-Connor, Elizabeth

AU - Knowler, William C.

PY - 2010/12

Y1 - 2010/12

N2 - OBJECTIVE - To assess the association between antidepressant medicine use and risk of developing diabetes during the Diabetes Prevention Program (DPP) and Diabetes Prevention Program Outcomes Study (DPPOS). RESEARCH DESIGN AND METHODS - DPP/DPPOS participants were assessed for diabetes every 6 months and for antidepressant use every 3 months in DPP and every 6 months in DPPOS for a median 10.0-year follow-up. RESULTS - Controlled for factors associated with diabetes risk, continuous antidepressant use compared with no use was associated with diabetes risk in the placebo (adjusted hazard ratio 2.34 [95% CI 1.32-4.15]) and lifestyle (2.48 [1.45-4.22]) arms, but not in the metformin arm (0.55 [0.25-1.19]). CONCLUSIONS - Continuous antidepressant use was significantly associated with diabetes risk in the placebo and lifestyle arms. Measured confounders and mediators did not account for this association, which could represent a drug effect or reflect differences not assessed in this study between antidepressant users and nonusers.

AB - OBJECTIVE - To assess the association between antidepressant medicine use and risk of developing diabetes during the Diabetes Prevention Program (DPP) and Diabetes Prevention Program Outcomes Study (DPPOS). RESEARCH DESIGN AND METHODS - DPP/DPPOS participants were assessed for diabetes every 6 months and for antidepressant use every 3 months in DPP and every 6 months in DPPOS for a median 10.0-year follow-up. RESULTS - Controlled for factors associated with diabetes risk, continuous antidepressant use compared with no use was associated with diabetes risk in the placebo (adjusted hazard ratio 2.34 [95% CI 1.32-4.15]) and lifestyle (2.48 [1.45-4.22]) arms, but not in the metformin arm (0.55 [0.25-1.19]). CONCLUSIONS - Continuous antidepressant use was significantly associated with diabetes risk in the placebo and lifestyle arms. Measured confounders and mediators did not account for this association, which could represent a drug effect or reflect differences not assessed in this study between antidepressant users and nonusers.

UR - http://www.scopus.com/inward/record.url?scp=78349290872&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78349290872&partnerID=8YFLogxK

U2 - 10.2337/dc10-1033

DO - 10.2337/dc10-1033

M3 - Article

VL - 33

SP - 2549

EP - 2551

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 12

ER -